Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Saag, Kenneth G. [1 ]
de Villiers, Tobie [2 ,3 ]
Alexandersen, Peter [4 ]
Jacobe, Heidi [5 ]
Kovarik, Carrie [6 ]
Werth, Victoria P. [7 ]
Leung, Albert [8 ]
Desai-Merchant, Avani [8 ]
Mattaliano, Julie [8 ]
Gurner, Deborah [8 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Rheumatol & Immunol, Birmingham, AL 35294 USA
[2] Univ Stellenbosch, Mediclin Panorama, Cape Town, South Africa
[3] Univ Stellenbosch, Dept Obstet & Gynecol, Cape Town, South Africa
[4] Ctr Clin & Basic Res, Vejle, Denmark
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA
[6] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[7] Philadelphia VAMC, Philadelphia, PA USA
[8] Merck & Co Inc, Kenilworth, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1026
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Long-term Outcomes With Ozanimod in the DAYBREAK Extension Trial by Number of MS Relapses During the Phase 3 Trials
    Freeman, L.
    Okai, A.
    Kappos, L.
    Cohen, J.
    Cheng, C.
    Riolo, J.
    Vermersch, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 283 - 284
  • [42] Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial
    Blom, Dirk
    Averna, Maurizio
    Meagher, Emma
    Theron, Hendrik du Toit
    Sirtori, Cesare
    Hegele, Robert
    Shah, Prediman
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni
    Foulds, Pam
    Bloedon, LeAnne
    Rader, Daniel
    Cuchel, Marina
    CIRCULATION, 2015, 132
  • [43] Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.
    Lewiecki, E. Michael
    Dinavahi, Rajani V.
    Lazaretti-Castro, Marise
    Ebeling, Peter R.
    Adachi, Jonathan D.
    Miyauchi, Akimitsu
    Gielen, Evelien
    Milmont, Cassandra E.
    Libanati, Cesar
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S24 - S24
  • [44] Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial
    Mari Wataya-Kaneda
    Hiroshi Nagai
    Yuuki Ohno
    Hiroo Yokozeki
    Yasuyuki Fujita
    Hironori Niizeki
    Kazue Yoshida
    Masaaki Ogai
    Yuichi Yoshida
    Akihiko Asahina
    Kazuyoshi Fukai
    Chiharu Tateishi
    Izumi Hamada
    Tatsuro Takahata
    Kenji Shimizu
    Shigeki Shimasaki
    Hiroyuki Murota
    Dermatology and Therapy, 2020, 10 : 635 - 650
  • [45] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
    Saag, Kenneth
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul D.
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [46] Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial
    Wataya-Kaneda, Mari
    Nagai, Hiroshi
    Ohno, Yuuki
    Yokozeki, Hiroo
    Fujita, Yasuyuki
    Niizeki, Hironori
    Yoshida, Kazue
    Ogai, Masaaki
    Yoshida, Yuichi
    Asahina, Akihiko
    Fukai, Kazuyoshi
    Tateishi, Chiharu
    Hamada, Izumi
    Takahata, Tatsuro
    Shimizu, Kenji
    Shimasaki, Shigeki
    Murota, Hiroyuki
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 635 - 650
  • [47] Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study
    Palacios, Santiago
    de Villiers, Tobie J.
    Nardone, Fiorenzo de Cicco
    Levine, Amy B.
    Williams, Robert
    Hines, Teresa
    Mirkin, Sebastian
    Chines, Arkadi A.
    MATURITAS, 2013, 76 (01) : 81 - 87
  • [48] Long-term safety and tolerability of atogepant for preventive treatment of migraine: a phase 3, 40-week, extension trial
    Klein, B.
    Miceli, R.
    Severt, L.
    McAllister, P.
    Mechtler, L.
    McVige, J.
    Diamond, M.
    Marmura, M.
    Guo, H.
    Finnegan, M.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 409 - 410
  • [49] Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older: Results from the ACTIVExtend Phase 3 Trial
    Greenspan, Susan
    Lorraine, Fitzpatrick
    Mitlak, Bruce
    Wang, Yamei
    Harvey, Nicholas C.
    Deal, Chad
    Cosman, Felicia
    Mcclung, Mike
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 115 - 115
  • [50] Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Saeki, Hidehisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB159 - AB159
12345